**SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.**
**(深圳市海普瑞藥業集團股份有限公司)**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock code: 9989)**

# VOLUNTARY ANNOUNCEMENT
# "ENOPARIN" OBTAINS APPROVAL FROM ARGENTINA

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the "**Company**", and together with its subsidiaries, the "**Group**") on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the "**Board**") is pleased to announce that Enoparin (an enoxaparin sodium injection and one of the Group's leading drugs) produced by Shenzhen Techdow Medicine Co., Ltd., a wholly-owned subsidiary of the Company, has been approved by the National Administration of Drugs, Food and Medical Devices of Argentina (ANMAT) for sales in the market:

## DETAILS OF THE LICENSE

| | | | |
|---|---|---|---|
| (I) | Product Name | : | Enoxaparin sodium injection |
| (II) | Registered Product Name | : | Enoparin |
| (III) | Dosage form | : | Injection |
| (IV) | Strength | : | 0.2ml: 20mg, 0.4ml: 40mg, 0.6ml: 60mg, 0.8ml: 80mg |
| (V) | Indications | : | 1. Prevention of venous thromboembolic diseases caused by medium to high-risk surgical procedures, especially in patients undergoing orthopedic or general surgery (including cancer surgery); |

2. Prevention of venous thromboembolic diseases in patients with acute diseases (such as acute heart failure, respiratory failure, severe infection, or rheumatic diseases) that cause movement restrictions and increase the risk of venous thromboembolism;

3. Treatment of deep vein thrombosis and pulmonary embolism, excluding pulmonary embolism requiring thrombolytic therapy or surgery;

4. Long-term treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism in patients with active cancer;

5. Prevention of thrombosis in the extracorporeal circulation during hemodialysis; and

6. Acute coronary syndrome:

   - Combined with aspirin, treatment of unstable angina and non-ST-segment elevation myocardial infarction; and

   - Treatment of acute ST-segment elevation myocardial infarction, including patients requiring medication or percutaneous coronary intervention (PCI).

(VI) Validity period of the license : 5 years

## BENEFIT AND IMPACT TO THE COMPANY

This approval means that the Group's enoxaparin sodium finish dose can be sold in the Argentine market, further enhancing the Group's market share of enoxaparin sodium finish dose worldwide. We believe that this approval is another important achievement in the international layout of the Group's finish dose business, once again proving the Group's ability to enter overseas markets. In the future, the Group will continue to exert efforts to accelerate the Group's expansion into the global market and the construction of sales channels, laying the groundwork for further strengthening the development of overseas markets.

As at the date of this announcement, the Group's enoxaparin sodium finish doses have been approved for sales in over 40 countries and regions around the world, including major markets such China, United States, European Union, United Kingdom, Switzerland, Poland, Brazil, Colombia, Chile, Canada, Saudi Arabia, United Arab Emirates, Malaysia, Australia, New Zealand and Thailand etc.

Announcement is hereby given.

By order of the Board
**Shenzhen Hepalink Pharmaceutical Group Co., Ltd.**
**Li Li**
*Chairman*

Shenzhen, the PRC
February 26, 2025

*As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Zhang Ping; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Huang Peng and Mr. Yi Ming.*